165 related articles for article (PubMed ID: 12692520)
21. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
22. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
23. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics and efficacy analysis for patients over 55 years of age with acute lymphoblastic leukemia].
Wang J; Huang XJ; Jiang B; Jiang Q; Lu XJ; Xu LP; Liu DH; Chen H; Bao L; Lu J; Zhu HH; Jiang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 45(6):938-44. PubMed ID: 24343078
[TBL] [Abstract][Full Text] [Related]
25. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
Thomas DA; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister FB; Cabanillas FF; Murphy S; Keating MJ; Kantarjian H
J Clin Oncol; 1999 Aug; 17(8):2461-70. PubMed ID: 10561310
[TBL] [Abstract][Full Text] [Related]
26. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
27. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
Thomas D; O'Brien S; Faderl S; Ravandi F; Jabbour E; Pierce S; Cortes J; Kantarjian H
Cancer; 2010 Oct; 116(19):4580-9. PubMed ID: 20572037
[TBL] [Abstract][Full Text] [Related]
28. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
[TBL] [Abstract][Full Text] [Related]
29. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period.
Ferrari A; Annino L; Crescenzi S; Romani C; Mandelli F
Leukemia; 1995 Oct; 9(10):1643-7. PubMed ID: 7564503
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
[TBL] [Abstract][Full Text] [Related]
31. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol.
Todeschini G; Tecchio C; Degani D; Meneghini V; Marradi P; Balter R; Zanotti R; Ricetti M; Franchini M; Perona G
Ann Oncol; 1997; 8 Suppl 1():77-81. PubMed ID: 9187436
[TBL] [Abstract][Full Text] [Related]
32. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Hunault-Berger M; Milpied N; Bernard M; Jouet JP; Delain M; Desablens B; Sadoun A; Guilhot F; Casassus P; Ifrah N
Leukemia; 2001 Jun; 15(6):898-902. PubMed ID: 11417474
[TBL] [Abstract][Full Text] [Related]
33. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
Stock W; Johnson JL; Stone RM; Kolitz JE; Powell BL; Wetzler M; Westervelt P; Marcucci G; DeAngelo DJ; Vardiman JW; McDonnell D; Mrózek K; Bloomfield CD; Larson RA
Cancer; 2013 Jan; 119(1):90-8. PubMed ID: 22744771
[TBL] [Abstract][Full Text] [Related]
34. Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
Mantadakis E; Smith AK; Hynan L; Winick NJ; Kamen BA
J Pediatr Hematol Oncol; 2002 Nov; 24(8):636-42. PubMed ID: 12439035
[TBL] [Abstract][Full Text] [Related]
35. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome.
Dabaja BS; O'Brien SM; Kantarjian HM; Cortes JE; Thomas DA; Albitar M; Schlette ES; Faderl S; Sarris A; Keating MJ; Giles FJ
Leuk Lymphoma; 2001 Jul; 42(3):329-37. PubMed ID: 11699397
[TBL] [Abstract][Full Text] [Related]
36. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
37. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
Todeschini G; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Zanotti R; Ricetti MM; Solero P; April F; Perona G
Leukemia; 1998 Feb; 12(2):144-9. PubMed ID: 9519775
[TBL] [Abstract][Full Text] [Related]
38. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia.
Sasaki K; Kantarjian H; Wierda W; Ravandi-Kashani F; Jorgensen J; Wang SA; Khoury J; Daver N; Burger J; Di Nardo CD; Jain N; Short NJ; Estrov Md Z; Konopleva Md PhD M; Ohanian DO M; Garcia-Manero G; Kadia T; Alvarado-Valero Y; Yilmaz M; Pierce S; Garris R; Ingram A; Cortes J; OʼBrien S; Jabbour E
Am J Hematol; 2020 Jul; 95(7):734-739. PubMed ID: 32170867
[TBL] [Abstract][Full Text] [Related]
40. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
